DS
VOR icon

David Shaw’s Vor Biopharma VOR Stock Holding History

David Shaw’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
+54,671
New +$827K ﹤0.01% 3747
2023
Q2 		– Sell
-574
Closed -$61.8K – 4583
2023
Q1 		$61.8K Sell
574
-1,971
-77% -$218K ﹤0.01% 4019
2022
Q4 		$338K Buy
+2,545
New +$252K ﹤0.01% 4040

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

David Shaw's VOR Position: Q2 2026 in Review

David Shaw opened a new position in Vor Biopharma (VOR) in Q2 2026: 54,671 shares worth $1.01M. The stake represents ﹤0.01% of the portfolio and ranks #3747 among its holdings. This is a return to the name: David Shaw previously reported a position in VOR as recently as Q1 2023.

David Shaw first reported a position in VOR in Q4 2022 and has held it in 3 quarters since. 101 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • David Shaw held 54,671 shares of Vor Biopharma worth $1.01M as of Q2 2026.
  • Vor Biopharma was a new David Shaw position in Q2 2026.
  • Vor Biopharma made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3747 holding.
  • David Shaw first reported a position in Vor Biopharma in Q4 2022 and has held it in 3 quarters since.
  • 101 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.